45 related articles for article (PubMed ID: 24567437)
1. Receipt of financial assistance for oral targeted therapy among older adults with advanced non-small cell lung cancer: A prospective cohort study.
Kumar A; Ragavan M; Velazquez AI; Zeng S; Wong ML
J Geriatr Oncol; 2024 Jun; 15(5):101746. PubMed ID: 38490915
[No Abstract] [Full Text] [Related]
2. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review.
Chouaïd C; Crequit P; Borget I; Vergnenegre A
Clinicoecon Outcomes Res; 2015; 7():9-15. PubMed ID: 25548525
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
Carlson JJ; Canestaro W; Ravelo A; Wong W
J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.
Carlson JJ; Suh K; Orfanos P; Wong W
Pharmacoeconomics; 2018 Apr; 36(4):495-504. PubMed ID: 29488070
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).
Lange A; Prenzler A; Frank M; Golpon H; Welte T; von der Schulenburg JM
BMC Pulm Med; 2014 Dec; 14():192. PubMed ID: 25471553
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
Liu W; Huo G; Chen P
Front Public Health; 2024; 12():1213318. PubMed ID: 38435286
[TBL] [Abstract][Full Text] [Related]
7. A framework for assessing the impact of accelerated approval.
Gould AL; Campbell RK; Loewy JW; Beckman RA; Dey J; Schiel A; Burman CF; Zhou J; Antonijevic Z; Miller ER; Tang R
PLoS One; 2022; 17(6):e0265712. PubMed ID: 35749431
[TBL] [Abstract][Full Text] [Related]
8. Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics.
Nenadić I; Staber J; Dreier S; Simons G; Schildgen V; Brockmann M; Schildgen O
Cancers (Basel); 2017 Jul; 9(7):. PubMed ID: 28696381
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Chhatwal J; Kanwal F; Roberts MS; Dunn MA
Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
[TBL] [Abstract][Full Text] [Related]
10. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad MM; Shaw AT
Clin Adv Hematol Oncol; 2014 Jul; 12(7):429-39. PubMed ID: 25322323
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?
Chouaid C; Borget I; Vergnenegre A
J Clin Oncol; 2014 Nov; 32(31):3577. PubMed ID: 25199755
[No Abstract] [Full Text] [Related]
12. Genotyping lung cancer is an investment in the future.
Azzoli CG; Engelman J; Fidias P; Gainor JF; Heist RS; Lamont EB; Lennes IT; Rosovsky RP; Sequist LV; Shaw AT; Temel JS
J Clin Oncol; 2014 Nov; 32(31):3576-7. PubMed ID: 25199750
[No Abstract] [Full Text] [Related]
13. Reply to C.G. Azzoli et al and C. Chouaid et al.
Leighl NB; Beca JM; Tsao MS; Hoch JS
J Clin Oncol; 2014 Nov; 32(31):3578-9. PubMed ID: 25199757
[No Abstract] [Full Text] [Related]
14. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
Lee JA; Bubendorf L; Stahel R; Peters S
Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost?
Kelly RJ; Hillner BE; Smith TJ
J Clin Oncol; 2014 Apr; 32(10):983-5. PubMed ID: 24567437
[No Abstract] [Full Text] [Related]
16. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
